

# UBS Equity Biotech


## Fund Fact Sheet

UBS Equity Funds &gt; UBS Sector Funds

### Fund description

- Actively managed equity portfolio investing worldwide in biotech companies.
- Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
- Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
- Investment decisions are based on a disciplined investment philosophy and fundamental research.

### Performance (share class Q-acc; basis USD, net of fees)<sup>1</sup>



Name of fund	UBS (Lux) Equity Fund – Biotech (USD)
Currency of fund	USD
Currency of share class	USD
Fund type	open-end
Accounting year end	30 November
Issue/redemption	daily
Swing pricing	Yes
Total fund assets (USD m)	1 001.39
Reference Index	MSCI US Investable Market Biotechnology 10/40 Index (r)
EU savings tax	not affected at distribution, not affected at sale/redemption

in %	1 year	2 years	3 years	Ø p.a. 2 years	Ø p.a. 3 years
Fund (USD)	-19.97	-16.33	25.04	-8.53	7.73
Ref. Index <sup>2</sup>	-17.96	-4.94	36.19	-2.50	10.84

<sup>1</sup> These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Source for all data and charts (if not indicated otherwise): UBS Asset Management

<sup>2</sup> Reference Index in currency of share class (without costs)

### Fund statistics

	3 years	5 years
Beta	1.02	1.00
Volatility <sup>1</sup>		
– Fund	28.18%	24.93%
– Reference Index	27.40%	24.53%
Sharpe ratio	0.22	0.73
Risk free rate	0.36%	0.31%

<sup>1</sup> Annualised standard deviation

### Share class details

	Q-acc
Net asset value (USD, 31.10.2016)	183.15
Last 12 months (USD)	– high – low
Share class assets (USD m)	75.40
Management fee p.a.	0.82%
Total expense ratio (TER) p.a.	1.08% <sup>1</sup>

<sup>1</sup> as at 30.11.2015

	Q-acc
ISIN	LU0400035332
Bloomberg	UBSBIQA LX
Launch date	12.11.2012
Distribution	Reinvestment

### How to contact UBS

Phone: +34-917-457 000  
Internet: [www.ubs.com/espanafondos](http://www.ubs.com/espanafondos)  
Contact your client advisor

### Portfolio management representatives

Nathalie Lötscher Petrus  
Scott Wilkin  
Christian Suter

# UBS Equity Biotech

## Country exposure (%)

	Fund	Deviation from index
United States	94.1	-5.9
Switzerland	2.6	+2.6
United Kingdom	2.0	+2.0
Belgium	0.9	+0.9
Global	0.3	+0.3
Netherlands	0.2	+0.2

## Key benefits

- Easy access to the global biotech sector.
- Offers investors broad diversification within the sector.
- The fund taps into the knowledge of proven sector specialists.
- UBS's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
- Investors benefit from a global investment platform of UBS Asset Management.

## 10 largest equity positions (%)

	Fund	Index
Gilead Sciences Inc	9.99	9.04
Amgen Inc	8.73	8.19
Celgene Corp	8.14	9.09
Biogen Inc	7.00	4.49
BioMarin Pharmaceutical Inc	5.80	4.59
Incyte Corp	4.75	4.66
AbbVie Inc	4.73	8.45
Vertex Pharmaceuticals Inc	4.70	4.26
Regeneron Pharmaceuticals Inc	4.38	4.40
Alkermes PLC	3.90	2.68

## Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

## Performance in % (net of fees, basis USD)<sup>1</sup>

Share class	2012	2013	2014	2015	2016 YTD <sup>3</sup>	LTD <sup>2</sup>	1 year	2 years	3 years	10 years	Ø p.a. 2 years
Q-acc	n.a.	56.22	42.73	2.61	-20.67	83.15	-19.97	-16.33	25.04	n.a.	-8.53
Ref. Index <sup>4</sup>	n.a.	67.21	35.39	14.30	-19.35	n.a.	-17.96	-4.94	36.19	n.a.	-2.50

<sup>1</sup> These figures refer to the past. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

Source for all data and charts (if not indicated otherwise): UBS Asset Management

<sup>2</sup> LTD: launch-to-date

<sup>3</sup> YTD: year-to-date (since beginning of the year)

<sup>4</sup> Reference Index in currency of share class (without costs)

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. CNMV registration number: . Representative in Spain for UBS funds established under foreign law: UBS Bank, S.A., MARÍA DE MOLINA, 4, E-28006 MADRID. Prospectuses, simplified prospectuses or Key investor information, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available free of charge from UBS, MARÍA DE MOLINA Nº 4, 28006 MADRID / AVENIDA DIAGONAL Nº 640, 2º A, E-08017 BARCELONA / FERNÁNDEZ Y GONZÁLEZ Nº 2, PLANTA PRINCIPAL, E-41001 SEVILLA / C/ROGER DE LAURIA Nº 7, 1ª PLANTA, 46002 VALENCIA / COSO Nº 33, 5º A, 50003 ZARAGOZA, CANTÓN PEQUEÑO 15, 4º, 15003 A CORUÑA. Before investing in a product please read the latest prospectus carefully and thoroughly. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS AG. Source for all data and charts (if not indicated otherwise): UBS Asset Management

© UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.